Top 5 Biotech Stocks To Invest In 2019

Generally speaking, companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But consider that with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).

Basically, these updates within the industry have the potential to make or break these companies.

Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA updates in February. We have added some color, a recent trading history and a consensus analyst price target.

Its worth mentioning that these dates may be subject to change due to various internal and outside factors. Some of these changes are positive developments, and some can be disasters if a company is deeply financed.

Top 5 Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.

Top 5 Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Brian Feroldi]

    The study in questionis called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

  • [By ]

    Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie  (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.

  • [By Cory Renauer]

    Patient Amgen Inc.(NASDAQ:AMGN) shareholders have seen the stock quadruple in price over the past decade, plus they’ve enjoyed one of the fastest-growing dividends in biopharma. Now that the company’s launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.

  • [By Joseph Griffin]

    South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.46 million shares from the previous level of 9.49 million. Shares were last seen at $171.94, in a 52-week trading range of $152.16 to $201.23.

Top 5 Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
    Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

Top 5 Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.

    Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded up about 19% at $355.17. The stocks 52-week range is $249.17 to $370.57. Volume was over 12 million compared to the daily average volume of 1.6 million.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stocks 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

  • [By Brian Orelli]

    Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earningsincrease in the first quarter. While revenue growth wasn’t as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren’t a sign of future trouble.

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

Leave a Reply

Your email address will not be published. Required fields are marked *